Stem cell therapy
Phase 1Cell therapy
Stem cell therapy is one of 20 biologic programs targeting Rotator Cuff Tear. It is currently in Phase 1.
1
Indications
9
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Rotator Cuff Tear
#DrugCompanyPhaseTrials
1IC-Green
PProvepharm SAS
Approved
Tylenol
KKenvue Brands
Approved
Ultram
WWim Janssens
Approved
Decadron
AAspen Global Incorporated
Approved
Marcaine
IInnocoll
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Naropin
FFresenius Kabi USA, LLC
Approved
Depo-Testosterone
AAzurity Pharmaceuticals
Approved
Suboxone
IIndivior Inc.
Approved
Valium
Akero TherapeuticsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Angiogenesis1 trial
Safety and Efficacy1 trial
Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve Disease
Unknown status·—·Phase 1/2·NCT01834079·24 enrolled
Parkinsonism1 trial
Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism
Unknown status·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·Phase 1/2·NCT01824121·25 enrolled
Dilated Cardiomyopathy1 trial
4 more indications
Autism1 trial
A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Autism
Unknown status·—·Phase 1/2·NCT01836562·100 enrolled
Cerebral Palsy1 trial
Rotator Cuff Tear1 trial
Clinical Study on the Safety and Efficacy of Tendon Stem Progenitor Cells Therapy for Rotator Cuff Tears
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT07320378·107 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Stem cell therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details